Viaderma Stock Performance
| VDRM Stock | USD 0.0004 0.0002 100.00% |
Viaderma holds a performance score of 14 on a scale of zero to a hundred. The entity has a beta of 10.36, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Viaderma will likely underperform. Use Viaderma jensen alpha and the relationship between the value at risk and day typical price , to analyze future returns on Viaderma.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Viaderma are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile basic indicators, Viaderma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Viaderma |
Viaderma Relative Risk vs. Return Landscape
If you would invest 0.02 in Viaderma on November 1, 2025 and sell it today you would earn a total of 0.02 from holding Viaderma or generate 100.0% return on investment over 90 days. Viaderma is currently generating 7.0278% in daily expected returns and assumes 37.9576% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Viaderma, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viaderma Target Price Odds to finish over Current Price
The tendency of Viaderma Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0004 | 90 days | 0.0004 | roughly 2.56 |
Based on a normal probability distribution, the odds of Viaderma to move above the current price in 90 days from now is roughly 2.56 (This Viaderma probability density function shows the probability of Viaderma Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 10.36 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Viaderma will likely underperform. In addition to that Viaderma has an alpha of 6.6048, implying that it can generate a 6.6 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Viaderma Price Density |
| Price |
Predictive Modules for Viaderma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Viaderma. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Viaderma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Viaderma is not an exception. The market had few large corrections towards the Viaderma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Viaderma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Viaderma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 6.60 | |
β | Beta against Dow Jones | 10.36 | |
σ | Overall volatility | 0.0001 | |
Ir | Information ratio | 0.18 |
Viaderma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Viaderma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Viaderma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Viaderma is way too risky over 90 days horizon | |
| Viaderma has some characteristics of a very speculative penny stock | |
| Viaderma appears to be risky and price may revert if volatility continues | |
| Viaderma has high likelihood to experience some financial distress in the next 2 years | |
| The company has a current ratio of 0.28, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Viaderma until it has trouble settling it off, either with new capital or with free cash flow. So, Viaderma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viaderma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viaderma to invest in growth at high rates of return. When we think about Viaderma's use of debt, we should always consider it together with cash and equity. | |
| Viaderma reported the previous year's revenue of 44.69 K. Net Loss for the year was (1.52 M) with profit before overhead, payroll, taxes, and interest of 37.63 K. | |
| Viaderma currently holds about 13.08 K in cash with (167.36 K) of positive cash flow from operations. |
Viaderma Fundamentals Growth
Viaderma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Viaderma, and Viaderma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viaderma Pink Sheet performance.
| Return On Asset | -0.91 | |||
| Operating Margin | (13.28) % | |||
| Current Valuation | 6.18 M | |||
| Shares Outstanding | 137.32 K | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 2.01 X | |||
| Revenue | 44.69 K | |||
| EBITDA | (592.43 K) | |||
| Cash And Equivalents | 13.08 K | |||
| Debt To Equity | 20.90 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (167.36 K) | |||
| Earnings Per Share | 0.16 X | |||
| Total Asset | 426.56 K | |||
| Retained Earnings | (7.38 M) | |||
| Current Asset | 185 K | |||
| Current Liabilities | 630 K | |||
About Viaderma Performance
By examining Viaderma's fundamental ratios, stakeholders can obtain critical insights into Viaderma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Viaderma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California. Viaderma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Viaderma performance evaluation
Checking the ongoing alerts about Viaderma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Viaderma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viaderma is way too risky over 90 days horizon | |
| Viaderma has some characteristics of a very speculative penny stock | |
| Viaderma appears to be risky and price may revert if volatility continues | |
| Viaderma has high likelihood to experience some financial distress in the next 2 years | |
| The company has a current ratio of 0.28, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Viaderma until it has trouble settling it off, either with new capital or with free cash flow. So, Viaderma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Viaderma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Viaderma to invest in growth at high rates of return. When we think about Viaderma's use of debt, we should always consider it together with cash and equity. | |
| Viaderma reported the previous year's revenue of 44.69 K. Net Loss for the year was (1.52 M) with profit before overhead, payroll, taxes, and interest of 37.63 K. | |
| Viaderma currently holds about 13.08 K in cash with (167.36 K) of positive cash flow from operations. |
- Analyzing Viaderma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viaderma's stock is overvalued or undervalued compared to its peers.
- Examining Viaderma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viaderma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viaderma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viaderma's pink sheet. These opinions can provide insight into Viaderma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.